Researchers at the University of Pennsylvania announced breakthrough early research news in treating advanced chronic lymphocytic leukemia (CLL) patients with genetically engineered versions of their own T cells. Following a flurry of articles about gene therapy and leukemia, how can you determine what this news could mean for you? In this podcast, we are joined by Dr. David Porter--the study's co-principal investigator--as he explains the details of the pilot trial and its possible impact on people living with leukemia.
|
David L. Porter, MD
Director, Blood and Marrow Transplantation, University of Pennsylvania Health System
Dr. David L. Porter is a professor of medicine at the Hospital of the University of Pennsylvania, where he is also director of blood and marrow transplantation. Dr. Porter earned a BA in biochemistry from the University of Rochester and his medical degree from Brown University. He received a fellowship in hematology/oncology at Harvard Medical School and Brigham and Women's...
more >
|
|
|
